A 35-year-old woman on combined oral contraceptive pills (COCPs) for 8 years presents with a 3-month history of breakthrough bleeding and irregular spotting. She is compliant with pill intake and has no signs of infection. Which investigation is most appropriate to exclude a serious underlying pathology and confirm that breakthrough bleeding is due to the contraceptive itself?

Explanation

## Investigation of Choice for Breakthrough Bleeding on COCPs ### Clinical Context Breakthrough bleeding (unscheduled vaginal bleeding) occurs in 10–30% of COCP users, especially in the first 3–6 months. While usually benign, it is essential to exclude serious pathology such as cervical polyps, fibroids, endometrial hyperplasia, or malignancy before attributing bleeding to the contraceptive. ### Why Transvaginal Ultrasound? **Key Point:** Transvaginal ultrasound with endometrial thickness measurement is the most appropriate investigation because it directly visualizes structural abnormalities of the uterus, endometrium, and ovaries while assessing endometrial thickness (a marker of endometrial pathology). ### Diagnostic Approach 1. **Transvaginal Ultrasound Findings:** - **Normal endometrial thickness:** < 4 mm in non-menstruating phase; reassures against endometrial hyperplasia or malignancy - **Structural lesions:** Polyps, submucosal fibroids, or adenomyosis may be visualized - **Ovarian cysts:** Functional cysts (common with hormonal contraception) can be differentiated from pathological masses 2. **Why This Approach?** - Non-invasive, rapid, and cost-effective - High sensitivity for detecting structural causes of abnormal bleeding - Helps differentiate contraceptive-related breakthrough bleeding from pathological bleeding **High-Yield:** In a woman on COCPs with breakthrough bleeding and normal transvaginal ultrasound, the bleeding is almost certainly due to the contraceptive (inadequate endometrial suppression or low-dose estrogen), and reassurance ± pill adjustment is appropriate. ### Diagnostic Algorithm ```mermaid flowchart TD A[Breakthrough bleeding on COCP]:::outcome --> B[Transvaginal ultrasound + endometrial thickness]:::action B --> C{Normal findings?}:::decision C -->|Yes| D[Endometrial thickness < 4 mm]:::outcome D --> E[Contraceptive-related breakthrough bleeding]:::outcome E --> F[Reassure; consider pill adjustment or continuation]:::action C -->|No| G[Abnormal findings detected]:::outcome G --> H[Polyp, fibroid, adenomyosis, or malignancy]:::outcome H --> I[Further evaluation: hysteroscopy, biopsy, or specialist referral]:::action ``` ### Comparison of Investigations | Investigation | Utility in Breakthrough Bleeding | Limitations | |---|---|---| | **Transvaginal ultrasound** | Visualizes structural lesions and measures endometrial thickness; excludes serious pathology | Operator-dependent; may miss small polyps | | **Pap smear/HPV testing** | Screens for cervical dysplasia and cancer | Does not evaluate uterine or endometrial pathology; not indicated for abnormal bleeding workup | | **Serum estradiol/progesterone** | Assesses hormone levels but does not visualize pathology | Hormonal levels fluctuate; not diagnostic for structural causes | | **Coagulation profile** | Indicated if heavy menstrual bleeding or family history of bleeding disorder | Not indicated for breakthrough bleeding; breakthrough bleeding is usually not due to coagulopathy | **Clinical Pearl:** Breakthrough bleeding on COCPs is a common, usually benign side effect. However, always exclude serious pathology (especially endometrial hyperplasia and malignancy in women > 40 years) with transvaginal ultrasound before reassuring the patient. **Warning:** Do not assume breakthrough bleeding is contraceptive-related without imaging. Endometrial cancer, though rare in this age group, can present as irregular bleeding and must be excluded. [cite:KD Tripathi 8e Ch 66]